



Kevin Hunt, Ph.D.

Co-Founder & CEO
Genuiti

Kevin Hunt is Cofounder and Chief Executive Officer of Genuiti Therapeutics, a Dallas-based company developing small molecule drugs aimed at GPR75, a genetically validated obesity target. At Genuiti he helped raise the Seed round, led the Series A, and built a highly capable R&D organization. Before that, as Chief Scientific Officer of Vanqua Bio, Kevin helped raise an \$85M Series B. He discovered VQ-101, a brain-penetrant GCase activator for Parkinson's disease that is now in the clinic. He also designed and discovered VQ-201, an oral C5aR1 antagonist, and led the scientific diligence behind its exclusive worldwide license to Biogen. That deal was worth up to \$1.06B, including \$70M upfront.

Earlier, at Edgewise Therapeutics, he discovered sevasemten (EDG-5506) for Becker and Duchenne muscular dystrophy in under 14 months from the initial screen. Edgewise later sold sevasemten to Servier for up to \$2.65B. Over more than two decades of finding new drugs, Kevin has been a named inventor on multiple clinical and preclinical candidates in neurodegeneration, oncology, neuromuscular disease and immunology.

Kevin grew up on a small farm in Erath County and earned his B.S. in Chemistry at Tarleton State University in Stephenville, where he ran varsity cross country. He went on to earn a Ph.D. in Organic Chemistry at Indiana University, followed by a postdoctoral fellowship at The Scripps Research Institute.

He began his career at Array BioPharma, where he delivered drug candidates across multiple therapeutic areas, including brain-penetrant BACE1 inhibitors from Array's neuroscience collaboration with Genentech, which he led.





Venture Dallas

2026 Annual Conference

He later opened and ran the Dallas outpost of Calico Life Sciences. At UT Southwestern Medical Center, he served at the same time as Director of Biopharmaceutical Product Development in the Office of Technology Development and as Head of Translational Science for the Center for Alzheimer's and Neurodegenerative Diseases. There he worked to build support among DFW stakeholders for a proof-of-concept fund to help academic discoveries become investable programs.

Kevin combines hands-on drug-hunting skill with company-building experience, and he is committed to growing Dallas as a place where new medicines are discovered and funded.

